Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study
- PMID: 28139443
- DOI: 10.1016/S2214-109X(17)30043-8
Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study
Abstract
Background: The 13-valent pneumococcal conjugate vaccine (PCV13) was designed to include disease-causing serotypes that are important in low-income and middle-income countries. Vaccine effectiveness estimates are scarce in these settings. South Africa replaced PCV7 with PCV13 in 2011 using a 2 + 1 schedule. We aimed to assess the effectiveness of two or more doses of PCV13 against invasive pneumococcal disease in children with HIV infection and in those not infected with HIV.
Methods: Cases of invasive pneumococcal disease in children aged 5 years or younger were identified through national laboratory-based surveillance. Isolates were serotyped with the Quellung reaction or PCR. We sought in-hospital controls for every case, matched for age, HIV status, and study site. We aimed to enrol four controls for every case not infected with HIV and six controls for every case with HIV infection (case-control sets). With conditional logistic regression, we calculated vaccine effectiveness as a percentage, with the equation 1 - [adjusted odds ratio for vaccination] × 100. We included data from an earlier investigation of PCV7 to assess vaccine effectiveness in children exposed to but not infected with HIV and in malnourished children not infected with HIV.
Findings: Between January, 2012, and December, 2014, we enrolled children aged 16 weeks or older to our study: 240 were cases not infected with HIV, 75 were cases with HIV infection, 1118 were controls not infected with HIV, and 283 were controls with HIV infection. The effectiveness of two or more doses of PCV13 against PCV13-serotype invasive pneumococcal disease was 85% (95% CI 37 to 96) among 11 case-control sets of children not infected with HIV and 91% (-35 to 100) among three case-control sets of children with HIV infection. PCV13 effectiveness among 26 case-control sets of children not infected with HIV was 52% (95% CI -12 to 79) against all-serotype invasive pneumococcal disease and 94% (44 to 100) for serotype 19A. Vaccine effectiveness against PCV7-serotype invasive pneumococcal disease was 87% (95% CI 38 to 97) in children exposed to HIV but uninfected and 90% (53 to 98) in malnourished children not infected with HIV.
Interpretation: Our results indicate that PCV13 in a 2 + 1 schedule is effective for preventing vaccine-type pneumococcal infections in young children not infected with HIV, including those who are malnourished or who have been exposed to HIV. Although the point estimate for PCV13 vaccine effectiveness in children infected with HIV was high, it did not reach significance, possibly because of the small sample size. These findings support recommendations for widespread use of pneumococcal conjugate vaccine in low-income and middle-income countries.
Funding: Gavi, The Vaccine Alliance.
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license. Published by Elsevier Ltd.. All rights reserved.
Comment in
-
13-valent pneumococcal conjugate vaccine in Africa.Lancet Glob Health. 2017 Mar;5(3):e244-e245. doi: 10.1016/S2214-109X(17)30044-X. Epub 2017 Jan 28. Lancet Glob Health. 2017. PMID: 28139442 No abstract available.
Similar articles
-
Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south africa: a matched case-control study.Clin Infect Dis. 2014 Sep 15;59(6):808-18. doi: 10.1093/cid/ciu431. Epub 2014 Jun 9. Clin Infect Dis. 2014. PMID: 24917657 Free PMC article.
-
Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.Clin Infect Dis. 2017 Jan 15;64(2):175-183. doi: 10.1093/cid/ciw720. Epub 2016 Oct 21. Clin Infect Dis. 2017. PMID: 27986682
-
Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.Vaccine. 2019 Jul 26;37(32):4491-4498. doi: 10.1016/j.vaccine.2019.06.071. Epub 2019 Jul 2. Vaccine. 2019. PMID: 31272872
-
Pneumococcal serotype evolution in Western Europe.BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. BMC Infect Dis. 2015. PMID: 26468008 Free PMC article. Review.
-
Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320. Clin Microbiol Infect. 2013. PMID: 24083785 Review.
Cited by
-
The metabolic, virulence and antimicrobial resistance profiles of colonising Streptococcus pneumoniae shift after PCV13 introduction in urban Malawi.Nat Commun. 2023 Nov 17;14(1):7477. doi: 10.1038/s41467-023-43160-y. Nat Commun. 2023. PMID: 37978177 Free PMC article.
-
Optimal age targeting for pneumococcal vaccination in older adults; a modelling study.Nat Commun. 2023 Feb 16;14(1):888. doi: 10.1038/s41467-023-36624-8. Nat Commun. 2023. PMID: 36797259 Free PMC article.
-
Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study.J Pediatric Infect Dis Soc. 2022 Sep 29;11(9):391-399. doi: 10.1093/jpids/piac038. J Pediatric Infect Dis Soc. 2022. PMID: 35640283 Free PMC article.
-
Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All.Vaccines (Basel). 2021 Nov 24;9(12):1390. doi: 10.3390/vaccines9121390. Vaccines (Basel). 2021. PMID: 34960136 Free PMC article. Review.
-
Streptococcus pneumoniae serotypes that frequently colonise the human nasopharynx are common recipients of penicillin-binding protein gene fragments from Streptococcus mitis.Microb Genom. 2021 Sep;7(9):000622. doi: 10.1099/mgen.0.000622. Microb Genom. 2021. PMID: 34550067 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical